Leah Fung, Ph.D.
About Leah Fung, Ph.D.
Leah Fung, Ph.D. - Chief Executive Officer
Leah Fung, Ph.D., serves as the Chief Executive Officer, bringing extensive leadership experience in the field of medicinal chemistry. Her career spans numerous influential roles across top-tier pharmaceutical companies. Her expertise lies in guiding research and development teams towards innovation in drug discovery and development.
Leah Fung, Ph.D. - Education and Expertise in Chemistry
Leah Fung earned her Ph.D. in chemistry from the University of California, Irvine. Her academic background provides a strong foundation for her work in medicinal chemistry. She is recognized for her expertise in combinatorial chemistry technologies and has contributed significantly to the advancement of this field through her research and leadership.
Leah Fung, Ph.D. - Professional Background in Medicinal Chemistry
Leah Fung’s professional journey in medicinal chemistry includes leadership roles at several notable companies. She served as Vice President of Medicinal Chemistry at NovoMedix and held the position of Associate Director at Structural Genomix, which was acquired by Eli Lilly. Earlier, she was the Assistant Director of Medicinal Chemistry at Structural Bioinformatics. Her career also includes significant research leadership roles at Signal Pharmaceuticals and Celgene.
Leah Fung, Ph.D. - Contributions to Combinatorial Chemistry Technologies
Leah Fung is a pioneer in combinatorial chemistry technologies. Her work in this area has been instrumental in advancing new methodologies for drug discovery. She has authored over 20 peer-reviewed publications and is a co-inventor on more than 40 issued U.S. patents and numerous international patents, showcasing her contributions to the field.